fda warning letter glp-1 october 2025 issued 30 letters to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's September crackdown on misleading FDA Sends Warning Letters to

GLP-1 receptor agonists now join this group as a class of agents with broad and expanding clinical implications

Those with conditions such as obesity, type 2 diabetes, or metabolic syndrome may benefit from the metabolic improvements offered by AOD 9604

Through the program, which runs through December 31, 2027, eligible Medicare beneficiaries can access certain GLP1 medications for $50 per month, offering more predictable and affordable pricing for patients who qualify

Verzola D, Picciotto D, Saio M, Aimasso F, Bruzzone F, Sukkar SG, et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 54.Glotfelty E.J., Olson L., Karlsson T.E., Li Y., Greig N.H

Disulfide-bond-induced structural frustration and dynamic disorder in a peroxiredoxin from MAS NMR